Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study - Nabholtz,J.; Pienkowski,T.; Mackey,J. (Proc Am Soc Clin Oncol, 2002)